BioAtla’s (BCAB) “Market Outperform” Rating Reiterated at JMP Securities

BioAtla (NASDAQ:BCAB)‘s stock had its “market outperform” rating reissued by stock analysts at JMP Securities in a research report issued to clients and investors on Thursday, Benzinga reports. They presently have a $12.00 target price on the stock. JMP Securities’ price target suggests a potential upside of 256.08% from the company’s previous close.

Separately, HC Wainwright decreased their price target on shares of BioAtla from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $14.20.

BioAtla Stock Performance

Shares of BCAB stock traded down $0.09 on Thursday, hitting $3.37. The company’s stock had a trading volume of 289,769 shares, compared to its average volume of 443,898. The stock’s 50 day moving average is $2.47 and its 200-day moving average is $2.08. BioAtla has a fifty-two week low of $1.24 and a fifty-two week high of $4.07. The company has a market capitalization of $161.56 million, a PE ratio of -1.32 and a beta of 1.02.

Institutional Investors Weigh In On BioAtla

Large investors have recently bought and sold shares of the company. Swiss National Bank lifted its holdings in shares of BioAtla by 17.8% in the first quarter. Swiss National Bank now owns 50,200 shares of the company’s stock worth $251,000 after acquiring an additional 7,600 shares during the last quarter. BlackRock Inc. boosted its position in BioAtla by 0.5% during the 1st quarter. BlackRock Inc. now owns 1,594,238 shares of the company’s stock worth $7,970,000 after buying an additional 8,344 shares during the period. Ergoteles LLC acquired a new stake in BioAtla during the 1st quarter worth approximately $79,000. Prudential Financial Inc. acquired a new position in shares of BioAtla in the 1st quarter worth approximately $130,000. Finally, XTX Topco Ltd acquired a new position in shares of BioAtla in the 1st quarter worth approximately $91,000. 77.23% of the stock is currently owned by institutional investors and hedge funds.

About BioAtla

BioAtla, Inc, a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.